Daratumumab in Primary Antiphospholipid Syndrome | MicrobiomeTrials← Back to trialsNCT05671757
Daratumumab in Primary Antiphospholipid Syndrome
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-05-26Est. Completion: 2028-05-05
Enrollment target: 22 participants Locations- Johns Hopkins University, Baltimore, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Northwell Health, Great Neck, New York, United States
- NYU Langone, New York, New York, United States
- Hospital for Special Surgery, New York, New York, United States
- Weill Cornell, New York, New York, United States
- Duke University, Durham, North Carolina, United States
Other microbiome trials you might be interested in
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1…
Gdansk, PolandEst. completion Nov 15, 2026
Takayasu's ArteritisGiant Cell ArteritisPolyarteritis NodosaRelapsing PolychondritisANCA-Associated Vasculitis
Background:
\- Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many me…
Bethesda, United StatesEst. completion Jan 1, 2050
Autoimmune Diseases
Background:
Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…
Bethesda, United StatesEst. completion Apr 22, 2030